Total Payments
$10,189
2024 Payments
$1,206
Companies
41
Transactions
583
Medicare Patients
7,983
Medicare Billing
$891,266
Payment Breakdown by Category
Food & Beverage$10,079 (98.9%)
Education$109.86 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,079 | 574 | 98.9% |
| Education | $109.86 | 9 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,509 | 118 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,468 | 63 | $0 (2024) |
| Genentech USA, Inc. | $1,001 | 53 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $847.16 | 62 | $0 (2024) |
| United Therapeutics Corporation | $683.81 | 26 | $0 (2024) |
| Insmed, Inc. | $538.38 | 29 | $0 (2024) |
| GENZYME CORPORATION | $400.94 | 17 | $0 (2024) |
| Grifols USA, LLC | $396.71 | 30 | $0 (2024) |
| Mylan Specialty L.P. | $291.38 | 22 | $0 (2024) |
| La Jolla Pharmaceutical Company | $243.87 | 11 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,206 | 66 | GlaxoSmithKline, LLC. ($289.90) |
| 2023 | $1,360 | 67 | GlaxoSmithKline, LLC. ($291.83) |
| 2022 | $965.78 | 62 | AstraZeneca Pharmaceuticals LP ($177.11) |
| 2021 | $1,304 | 69 | AstraZeneca Pharmaceuticals LP ($322.07) |
| 2020 | $758.81 | 51 | Boehringer Ingelheim Pharmaceuticals, Inc. ($183.88) |
| 2019 | $1,501 | 93 | Genentech USA, Inc. ($381.96) |
| 2018 | $1,512 | 85 | Genentech USA, Inc. ($371.23) |
| 2017 | $1,582 | 90 | AstraZeneca Pharmaceuticals LP ($239.53) |
All Payment Transactions
583 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Respiratory | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Immunology | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: RESPIRATORY | ||||||
| 11/27/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Pulmonology | ||||||
| 11/26/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: RESPIRATORY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: Immunology | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Respiratory | ||||||
| 10/30/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/16/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: IMMUNOLOGY | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Respiratory | ||||||
| 10/09/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: RESPIRATORY | ||||||
| 10/08/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: Respiratory | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 09/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Respiratory | ||||||
| 09/04/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/03/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,662 | 2,718 | $553,064 | $163,432 |
| 2022 | 24 | 2,026 | 3,833 | $770,836 | $227,854 |
| 2021 | 27 | 2,162 | 4,113 | $820,636 | $243,880 |
| 2020 | 28 | 2,133 | 4,203 | $824,800 | $256,101 |
Total Patients
7,983
Total Services
14,867
Medicare Billing
$891,266
Procedure Codes
98
All Medicare Procedures & Services
98 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 174 | 482 | $101,220 | $43,220 | 42.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 324 | 732 | $111,264 | $42,455 | 38.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 201 | 291 | $37,830 | $17,116 | 45.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 116 | 183 | $41,175 | $15,955 | 38.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 97 | 98 | $41,650 | $11,606 | 27.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 243 | 360 | $66,600 | $6,257 | 9.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 52 | 52 | $15,600 | $5,710 | 36.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 55 | 55 | $15,125 | $4,784 | 31.6% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 47 | 53 | $39,750 | $2,903 | 7.3% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Office | 2023 | 30 | 30 | $7,500 | $2,494 | 33.2% |
| 71045 | X-ray of chest, 1 view | Office | 2023 | 96 | 125 | $28,175 | $2,063 | 7.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 40 | 49 | $5,635 | $1,842 | 32.7% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 25 | 25 | $2,500 | $1,798 | 71.9% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 74 | 76 | $20,900 | $1,773 | 8.5% |
| 31622 | Diagnostic exam of lung airway using an endoscope | Facility | 2023 | 11 | 12 | $9,900 | $1,175 | 11.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 28 | 28 | $1,400 | $796.32 | 56.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 16 | 21 | $3,150 | $786.98 | 25.0% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 17 | 17 | $3,400 | $454.08 | 13.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 16 | 29 | $290.00 | $243.60 | 84.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 436 | 1,528 | $232,256 | $81,551 | 35.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 173 | 532 | $111,720 | $41,126 | 36.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 135 | 141 | $59,925 | $20,563 | 34.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 190 | 209 | $57,475 | $20,088 | 35.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 172 | 233 | $30,290 | $14,034 | 46.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 109 | 143 | $32,175 | $11,728 | 36.4% |
About Dr. Roy Fox, MD
Dr. Roy Fox, MD is a Pulmonary Disease healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1972594208.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roy Fox, MD has received a total of $10,189 in payments from pharmaceutical and medical device companies, with $1,206 received in 2024. These payments were reported across 583 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($10,079).
As a Medicare-enrolled provider, Fox has provided services to 7,983 Medicare beneficiaries, totaling 14,867 services with total Medicare billing of $891,266. Data is available for 4 years (2020–2023), covering 98 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location Memphis, TN
- Active Since 11/04/2005
- Last Updated 11/12/2019
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1972594208
Products in Payments
- TRELEGY ELLIPTA (Drug) $743.30
- NUCALA (Biological) $504.60
- ORENITRAM (Drug) $470.91
- Arikayce (Drug) $464.76
- OFEV (Drug) $456.82
- DUPIXENT (Biological) $432.56
- BREZTRI (Drug) $417.89
- Xolair (Biological) $395.05
- Prolastin-C Liquid (Biological) $280.82
- Esbriet (Biological) $241.50
- AVYCAZ (Drug) $233.33
- TYVASO (Drug) $212.90
- GIAPREZA (Drug) $197.96
- FASENRA (Biological) $193.42
- TEZSPIRE (Biological) $172.68
- ACTHAR (Biological) $170.33
- STIOLTO RESPIMAT (Drug) $152.54
- ANORO (Drug) $141.97
- AEROGEN SOLO NEBULIZER SYSTEM (Device) $138.99
- DUPIXENT (Drug) $138.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Memphis
Anthony Mattox, D.o, D.O
Pulmonary Disease — Payments: $21,781
Pulmonary Disease $21,781
Dr. Nathan Wilds, Md, MD
Pulmonary Disease — Payments: $20,941
Pulmonary Disease $20,941
Jeffrey Wright, M.d, M.D
Pulmonary Disease — Payments: $15,147
Pulmonary Disease $15,147
Robert Aguillard, Md, MD
Pulmonary Disease — Payments: $11,075
Pulmonary Disease $11,075
Dr. Kimberly Marsh, M.d, M.D
Pulmonary Disease — Payments: $9,654
Pulmonary Disease $9,654
Paul Deaton, Md, MD
Pulmonary Disease — Payments: $9,582
Pulmonary Disease $9,582